The US is often seen, quite rightly, as a market opportunity for Europe’s pharmaceutical companies, but it can also be an unpredictable market where setbacks can rapidly follow each other in what might seem as an unremitting sequence. Barcelona, Spain-headquartered Almirall SA has just been afflicted by three such setbacks, leading to a lowering in its sales and earnings guidance for 2017.
Almirall’s US business, Aqua, has been adversely impacted by what seems to be the inappropriate use of its patient assistance...








